DiscGenics completes enrollment of cell therapy trial for degenerative disc disease

Spinal Tech

Biopharmaceutical company DiscGenics recently finished enrollment for its clinical trial of IDCT, an allogeneic, injectable disc cell therapy for degenerative disc disease.

Three insights:

1. IDCT's safety and efficacy will be evaluated in 60 participants with single-level, mild to moderate lumbar degenerative disc disease.

2. The Phase 1/2 clinical trial aims to show IDCT's ability to reduce inflammation and restore disc height.

3. The prospective, randomized trial will take place at 14 centers in 12 states.

Copyright © 2024 Becker's Healthcare. All Rights Reserved. Privacy Policy. Cookie Policy. Linking and Reprinting Policy.

 

Featured Webinars

Featured Whitepapers